RYBREVANT ® (amivantamab-vmjw) Provides Higher Activity and Longer Duration of Response When Used in Combination with Lazertinib in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer Who Have Failed Osimertinib
September 19, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson &Johnson today announced a new analysis from the CHRYSALIS (NCT02609776) study evaluating RYBREVANT® (amivantamab-vmjw) monotherapy and a combination regimen with lazertinib in advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations who progressed after osimertinib. The analysis showed higher activity and longer duration of response (DOR) in patients treated with the combination therapy, demonstrating the potential benefit of targeting the extracellular (outer) and catalytic (internal) domains of EGFR, even in patients with documented resistance to third-generation EGFR tyrosine kinase inhibitors (TKIs).1 The results were presented in a mini-oral presentation at the European Society for Medical Oncology (ESMO) Annual Congress 2021 virtual meeting on Sunday, September 19 (Abstract #1192MO).“Despite advances in targeted therapies, non-small cell lung cancer with EGFR mutations remains a disease with considerable unmet need, especially when prior standard treatments have failed,” said Natasha B. Leighl, M.D., MMSc, FRCPC, FASCO, Lung Medical Oncology Lead, Princess Margaret Cancer Centre in Toronto, Canada, and presenting study investigator.† “This analysis shows that targeting two domains of EGFR using amivantamab and lazertinib combination therapy demonstrated higher and more durable response than tar...
ConclusionsOlanzapine use is associated with an increased risk of major congenital malformations and specifically, musculoskeletal malformations. Use during pregnancy should be restricted to situations where no safer alternatives exist.
ConclusionThe CYP2C19 IMs, PMs, and the number of targeted vessels are essential factors associated with MACE risk in dual clopidogrel-treated Uygur population with ACS following PCI. These data provide valuable insights into the genetic polymorphisms affecting clopidogrel response among minority groups in China.
ConclusionThe majority of patient-reported ADRs were non-serious. However, a relevant number of non-labelled even serious ADRs was reported for novel compounds by patients. Despite well-known limitations of patient-reported ADRs, this web-based ADR reporting system contributes to the identification of new ADRs and thus can help to improve patients ’ safety complementing other pharmacovigilance instruments.
AbstractPurposeThe trial aimed to investigate the effectiveness of exogenous melatonin as an adjuvant to pregabalin for relief of pain in patients suffering from painful diabetic neuropathy (PDN).Patients and methodsThis randomized, double-blind, placebo-controlled trial was carried out between October 2019 and December 2020 in an outpatient specialty clinic in Iran. One-hundred-three type 2 diabetic patients suffering from PDN were randomized into either the melatonin group (n = 52) or the placebo group (n = 51). Besides pregabalin at a dose of 150 mg per day, patients started with melato...
According to the American Cancer Society, about 1 in 5 cancers in the US and about 1 in 6 cancer deaths can be linked to poor nutrition, being overweight, not exercising, or alcohol.WebMD Health News
This study aimed to understand the extent to which cannabis-related risk perception and COVID-19-related health worries were associated with the reported reduction in sharing cannabis smoking products to mitigate the risk of the coronavirus transmission or infection. This association was tested in two different periods in terms of toughness of national lockdown policy imposed in the first months of the pandemic in Israel. The study population included adult recreational cannabis users who completed one of the two online cross-sectional surveys dedicated to COVID-19 and the cannabis use situation in Israel in the first h...
OHSU's vaccination results are in line with other major Portland health systems.
The FDA has followed the advice of its advisory panels, approving additional doses of Moderna and J&J vaccines, and opening up people's options by letting them switch vaccine type for their booster.FDA Approvals
Both Iterion and Moleculin are moving their drug candidates through the regulatory pipeline.
More News: Adenocarcinoma | Alcoholism | Alimta | Allergy & Immunology | Biotechnology | Brain | Brain Cancers | Canada Health | Cancer | Cancer & Oncology | Cancer Vaccines | Carcinoma | Cardiology | Cardiovascular | Chemotherapy | Clinical Trials | Conferences | Constipation | Corticosteroid Therapy | Cough | Dermatitis | Dermatology | Epidemiology | Epithelial Cancer | Food and Drug Administration (FDA) | Headache | Health Management | Heart | Hypertension | Immunotherapy | Infectious Diseases | International Medicine & Public Health | Interstitial Lung Disease | Laboratory Medicine | Learning | Legislation | Lung Cancer | Migraine | Neurology | Neuroscience | Non-Small Cell Lung Cancer | Opthalmology | Oral Cancer | Pain | Pharmaceuticals | Pneomococcal Vaccine | Politics | Potassium | Pregnancy | Pulmonary Hypertension | Science | Singapore Health | Skin | Skin Cancer | Sodium | South Korea Health | Squamous Cell Carcinoma | Statistics | Study | Tarceva | Toxicology | Universities & Medical Training | Vaccines | Veterinary Vaccinations | Websites | WHO